The next generation of biotech CEOs isn't defined by science alone. It's shaped by the ability to turn innovation into global commercial success.
Dr. Uday Harle has been appointed Chief Executive Officer at Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare Ltd., after a 25 year career in biologics, biosimilars, vaccines, and global clinical development.
After earning his PhD in Medicine and building his research foundation at AIIMS, he held leadership roles at Ferring Pharmaceuticals,Bharat Serums and Vaccines Limited, Abbott Healthcare India, and Amneal Pharmaceuticals, leading clinical development, pharmacovigilance, global regulatory strategy, and biologics innovation across US FDA, EMA, ANVISA, and CDSCO.
As CEO, he will lead Shilpa Biologicals' next phase of growth, accelerating its biologics, biosimilars, and Antibody Drug Conjugate (ADC) portfolio while strengthening its global innovation strategy.
His appointment reflects a broader industry shift. Biopharma companies are increasingly choosing leaders who combine scientific excellence, global regulatory expertise, clinical development, and business leadership to scale innovation into sustainable growth.
At Boardroom CXO, we're seeing strong demand for leaders who can bridge research, regulation, and commercial strategy in the rapidly evolving biologics ecosystem.
Question for biopharma leaders: What's the bigger challenge today, advancing ADC and CAR T innovation, or navigating increasingly complex global regulatory pathways to bring therapies to market faster?
First published on the Boardroom CXO LinkedIn page on 6 August 2026. To correct or remove it, write to [email protected].
Boardroom CXO runs executive search for CXO and senior leadership roles in India and the UAE. Talk to us about a leadership hire.
